Erythropoietin and myocardial protection: What's new?

Fundamental and Clinical Pharmacology

Volumn 19, Issue 4, 2005, Pages 439-446

  Joyeux Faure, M ^a   Godin Ribuot, D ^a   Ribuot, C ^a  

^a Domaine de la Merci   (France)

Author keywords

Apoptosis; Cardioprotection; Erythropoietin; Functional recovery; Infarction; Signaling pathways

Indexed keywords

JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; POTASSIUM CHANNEL; PROTEIN KINASE C; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; STAT5 PROTEIN;

ANEMIA; APOPTOSIS; CHRONIC KIDNEY FAILURE; ERYTHROPOIESIS; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; REVIEW;

ANIMALS; APOPTOSIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEART; HUMANS; POTASSIUM CHANNELS; PROTECTIVE AGENTS; SIGNAL TRANSDUCTION; VENTRICULAR FUNCTION, LEFT;

EID: 22344433541     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00347.x     Document Type: Review

References (47)

1. Williams R.S., Benjamin I.J. Protective responses in the ischemic myocardium. J. Clin. Invest. (2000) 106 813-818.
2. Kloner R.A., Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2004? J. Am. Coll. Cardiol. (2004) 44 276-286.
3. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation (1986) 74 1124-1136.
4. Bolli R. The late phase of preconditioning. Circ. Res. (2000) 87 972-983.
5. Bogoyevitch M.A. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc. Res. (2004) 63 208-216.
6. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA (2003) 100 4802-4806.
7. Sadamoto Y., Igase K., Sakanaka M., et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem. Biophys. Res. Commun. (1998) 253 26-32.
8. Bernaudin M., Marti H.H., Roussel S., et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. (1999) 19 643-651.
9. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. USA (2000) 97 10526-10531.
10. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. (2002) 8 495-505.
11. Tramontano A.F., Muniyappa R., Black A.D., et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. (2003) 308 990-994.
12. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. (2003) 112 999-1007.
13. Cai Z., Manalo D.J., Wei G., et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation (2003) 108 79-85.
14. Parsa C.J., Kim J., Riel R.U., et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem. (2004) 279 20655-20662.
15. Lipsic E., van der Meer P., Henning R.H., et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. (2004) 44 473-479.
16. Cai Z., Semenza G.L. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation (2004) 109 2050-2053.
17. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. (2004) 18 1031-1033.
18. Shi Y., Rafiee P., Su J., Pritchard K.A. Jr, Tweddell J.S., Baker J.E. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol. (2004) 99 173-182.
19. Rafiee P., Shi Y., Su J., Pritchard K.A. Jr, Tweddell J.S., Baker J.E. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res. Cardiol. (2004).
20. Moon C., Krawczyk M., Ahn D., et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl Acad. Sci. USA (2003) 100 11612-11617.
21. van der Meer P., Lipsic E., Henning R.H., et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur. J. Heart Fail. (2004) 6 853-859.
22. Digicaylioglu M., Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature (2001) 412 641-647.
23. Siren A.L., Knerlich F., Poser W., Gleiter C.H., Brack W., Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. (Berl.) (2001) 101 271-276.
24. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation (2002) 106 2973-2979.
25. Scarabelli T., Stephanou A., Rayment N., et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation (2001) 104 253-256.
26. Cheung W.K., Goon B.L., Guilfoyle M.C., Wacholtz M.C. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin. Pharmacol. Ther. (1998) 64 412-423.
27. Erbayraktar S., Grasso G., Sfacteria A., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl Acad. Sci. USA (2003) 100 6741-6746.
28. Fiordaliso F., Chimenti S., Staszewsky L., et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA (2005) 102 2046-2051.
29. Juul S.E., Yachnis A.T., Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. (1998) 52 235-249.
30. Witthuhn B.A., Quelle F.W., Silvennoinen O., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell (1993) 74 227-236.
31. Smith K.J., Bleyer A.J., Little W.C., Sane D.C. The cardiovascular effects of erythropoietin. Cardiovasc. Res. (2003) 59 538-548.
32. Klingmuller U. The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells-signals emanating from the erythropoietin receptor. Eur. J. Biochem. (1997) 249 637-647.
33. Dawn B., Guo Y., Rezazadeh A., et al. Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J. Mol. Cell Cardiol. (2004) 37 51-61.
34. Onai Y., Suzuki J., Kakuta T., et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc. Res. (2004) 63 51-59.
35. Brines M., Grasso G., Fiordaliso F., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl Acad. Sci. USA (2004) 101 14907-14912.
36. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. (1999) 13 2905-2927.
37. Cheung J.Y., Miller B.A. Molecular mechanisms of erythropoietin signaling. Nephron (2001) 87 215-222.
38. Wu X.C., Johns E.J., Richards N.T. Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells. Clin. Sci. (Lond.) (1999) 97413-97419.
39. Ito K., Sato T., Arita M. Protein kinase C isoform-dependent modulation of ATP-sensitive K+ channels during reoxygenation in guinea-pig ventricular myocytes. J. Physiol. (2001) 532165-532174.
40. Baines C.P., Cohen M.V., Downey J.M. Signal transduction in ischemic preconditioning: the role of kinases and mitochondrial K(ATP) channels. J. Cardiovasc. Electrophysiol. (1999) 10 741-754.
41. Baines C.P., Zhang J., Wang G.W., et al. Mitochondrial PKC-epsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Cire. Res. (2002) 90 390-397.
42. + channels in the cardiac inner mitochondrial membrane. Science (2002) 298 1029-1033.
43. Baker E.J., Boerboom L.E., Olinger G.N., Baker J.E. Tolerance of the developing heart to ischemia: impact of hypoxemia from birth. Am. J. Physiol. (1995) 268 H1165-H1173.
44. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. (2001) 37 1775-1780.
45. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood (2003) 102 1340-1346.
46. van der Meer P., Voors A.A., Lipsic E., van Gilst W.H., van Veldhuisen D.J. Erythropoietin in cardiovascular diseases. Eur. Heart J. (2004) 25 285-291.
47. Coleman T., Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit. Care (2004) 8 337-341.